A1C Almanac

Main Page

Mechanistic Promise Versus Clinical Modesty of Berberine in Fat Loss and Cardiometabolic Risk Reduction Among Adults With Metabolic Dysregulation

Posted

by

dr Karunia Valeriani Japar

Table of Contents
Category:
Tags: , , ,

Keywords: AMPK Activation, Berberine, Fat Loss, Insulin Resistance, Metabolic Health

Why Berberine Became a “Fat Loss” Darling

Berberine is an isoquinoline alkaloid isolated from several medicinal plants, most notably species within the Berberis genus, and has a long history of use in traditional Chinese and Ayurvedic medicine for the management of gastrointestinal infections and diarrhea. Historically, its clinical applications were largely confined to antimicrobial and anti‑diarrheal indications, reflecting both its local effects on the gut and its broad antimicrobial activity. Over the past two decades, however, berberine has progressively migrated from the realm of traditional medicine into the evidence‑based metabolic health conversation, driven by accumulating preclinical and early clinical data.

The contemporary fascination with berberine as a “fat loss” agent emerged when experimental studies began to demonstrate favourable effects on key nodes of metabolic regulation, including improvements in insulin sensitivity, lipid profiles, and hepatic steatosis. In rodent and cellular models, berberine was shown to activate AMP‑activated protein kinase (AMPK), enhance glucose uptake, reduce de novo lipogenesis, and ameliorate fatty liver changes findings that collectively suggested a plausible role in weight regulation and cardiometabolic risk reduction. As these mechanistic and surrogate‑marker benefits were translated into small human trials, the narrative around berberine rapidly expanded beyond glycaemic control to encompass body‑weight management, with preliminary reports of modest reductions in body mass index and waist circumference afurther fuelling enthusiasm.

This mechanistic promise, amplified through social media and the wellness supplement industry, has led to berberine being popularly framed as a “natural Ozempic” or over‑the‑counter GLP‑1 analogue, often marketed as a direct fat‑burning solution. The resulting gap between public perception and the actual strength of the clinical evidence is substantial: while there is a biologically coherent rationale for metabolic benefit, the magnitude and consistency of effects on adiposity and long‑term weight loss remain far more modest than promotional narratives suggest. The present article therefore aims to critically appraise berberine’s role in fat loss and metabolic health by juxtaposing mechanistic and preclinical enthusiasm against the totality of available clinical data on body weight, body composition, and broader metabolic outcomes. In doing so, it seeks to reposition berberine not as a standalone pharmacologic solution for obesity, but as a potential adjunctive tool that may complement, rather than replace foundational lifestyle interventions and guideline-directed therapies in selected patients.

Mechanisms Promise: Why Berberine Looks Great on Paper

Berberine’s appeal as a metabolic modulator is rooted in a dense body of mechanistic work showing that it engages central energy‑sensing pathways in liver, muscle, and adipose tissue. At the core of this literature is its ability to activate AMP‑activated protein kinase (AMPK), a key cellular “fuel gauge” that is switched on when energy status is low. In hepatocytes, skeletal myotubes, and adipocytes, berberine increases AMPK phosphorylation, in part through mild inhibition of mitochondrial respiratory complex I, thereby raising the AMP:ATP ratio and triggering downstream catabolic programs. Activation of AMPK leads to inhibitory phosphorylation of acetyl‑CoA carboxylase (ACC), lowering malonyl‑CoA levels, relieving inhibition of carnitine palmitoyltransferase‑1, and facilitating mitochondrial fatty acid entry and oxidation. Concomitantly, berberine stimulates GLUT4 translocation to the plasma membrane in muscle cells in an insulin‑independent manner, enhancing glucose uptake and improving cellular glucose disposal. Collectively, these actions shift the balance away from energy storage and toward increased ATP generation, providing a biologically coherent rationale for its proposed effects on adiposity and glycaemic control [1,2,3,4,5,6].

The effects of berberine on adipocyte biology further strengthen this mechanistic promise. In 3T3‑L1 adipocytes and other adipose models, berberine reduces neutral lipid accumulation, an effect closely linked to AMPK activation and downstream modulation of lipid‑handling genes. Gene‑expression studies in obese rodent models demonstrate upregulation of enzymes involved in fatty acid oxidation, such as carnitine palmitoyltransferase‑1, medium‑chain acyl‑CoA dehydrogenase, and components of the PPARα/PGC‑1α axis, together with suppression of lipogenic factors including SREBP-1c and fatty acid synthase. Berberine also appears to remodel adipose tissue phenotype by engaging AMPK–SIRT1–PPARγ pathways, promoting “browning” of white adipocytes, increasing thermogenesis‑related gene expression (for example, UCP1), and enhancing fatty acid oxidation capacity. In parallel, preclinical data suggest an AMPK‑dependent upregulation of adipose triglyceride lipase and related lipolytic machinery, which may support greater mobilization and turnover of stored triglycerides, thereby providing a mechanistic link between chronic berberine exposure and the prevention of diet‑induced obesity in animal models [2,4,5,7,8,9,10].

Beyond direct effects on adipocytes and classical metabolic tissues, berberine exerts multi‑organ actions along the gut–liver–adipose axis that may indirectly influence fat mass and insulin sensitivity. Experimental studies in rodents and avian models indicate that berberine can remodel the gut microbiota, increasing the relative abundance of beneficial taxa while curbing lipopolysaccharide‑producing gram‑negative bacteria, thereby reducing endotoxin‑driven activation of TLR4/NF‑κB signalling and downstream inflammatory cascades linked to insulin resistance. Berberine also modifies bile acid profiles and activates intestinal and hepatic farnesoid X receptor (FXR) signalling, which in turn affects hepatic lipid metabolism and glucose homeostasis. In obese rodent models, these gut‑mediated effects converge with hepatic AMPK activation to reduce hepatic steatosis, improve triglyceride handling, and normalize key lipoprotein abnormalities. Translating to humans, early‑phase trials and mechanistic studies report reductions in circulating C‑reactive protein and other inflammatory markers alongside improvements in lipid profiles and glycaemic indices, suggesting that berberine’s potential cardiometabolic benefits extend beyond weight change per se. Together, these preclinical and translational data explain why berberine “looks great on paper” as a multi‑target metabolic intervention with plausible relevance for obesity, insulin resistance, and associated cardiometabolic risk [2,4,6,11,12].

Clinical Reality: What Human Trials Actually Show

Across human studies, berberine’s effects on body weight and adiposity are measurable but modest rather than transformative. Recent systematic reviews and meta‑analyses of randomized controlled trials in adults with obesity, type 2 diabetes, or metabolic syndrome report small but statistically significant reductions in body weight (on the order of 1–2 kg), body mass index (BMI), and waist circumference over interventions typically lasting 8–24 weeks. One meta‑analysis of 23 trials found mean differences of approximately −0.9 kg for body weight, −0.5 kg/m² for BMI, and −1.3 cm for waist circumference compared with control, highlighting a signal in favour of berberine but of a magnitude more consistent with an adjunctive nutraceutical than a primary weight‑loss pharmacotherapy. Notably, umbrella reviews focusing on obesity indices and lipid outcomes emphasize that while waist circumference and some lipid parameters improve robustly, pooled effects on absolute body weight and BMI are smaller and, in some analyses, lose statistical significance, underscoring heterogeneity across studies. Several individual randomized trials report clear improvements in glycaemic control, triglycerides, or inflammatory markers without parallel, clinically meaningful changes in BMI, reinforcing the conclusion that berberine’s metabolic benefits can occur in the absence of substantial weight loss. Across this literature, sample sizes are generally in the tens to low hundreds, follow‑up is short to medium term, and post‑discontinuation data are sparse, so the durability of any weight‑related effects and their relevance to long‑term weight‑maintenance remain uncertain [13,14,15,16,17].

Beyond simple anthropometrics, several lines of evidence suggest more pronounced effects of berberine‑based formulations on visceral adiposity and hepatic steatosis. In a phase 2, proof‑of‑concept randomized controlled trial of berberine ursodeoxycholate (BUDCA) in adults with type 2 diabetes and presumed NASH, 18 weeks of high‑dose therapy (1000 mg twice daily) produced a significantly greater absolute reduction in MRI‑proton‑density fat fraction liver fat content compared with placebo (mean −4.8% vs −2.0%), alongside improvements in HbA1c, liver enzymes, and serum lipids. Participants receiving the higher BUDCA dose also experienced modest but statistically significant weight loss over the study period, with mean reductions in body weight in the range of 3–4 kg relative to baseline. These findings are complemented by smaller clinical studies and meta‑analyses in metabolic dysfunction–associated steatotic liver disease (MASLD), which consistently show reductions in liver fat surrogates, aminotransferases, and markers of insulin resistance, even when changes in scale weight are limited. Taken together, the data suggest that berberine’s strongest human signals lie in improvement of hepatic steatosis, glycaemic control, and dyslipidaemia, with attendant reductions in cardiometabolic risk, rather than in large, standalone reductions in total body mass or overt obesity remission [15,18,19,20,21].

Evidence in metabolic syndrome and antipsychotic‑associated weight gain further illustrates this pattern of metabolic benefit with modest anthropometric change. A systematic review and meta‑analysis of randomized placebo‑controlled trials in metabolic syndrome found that adjunctive berberine significantly improved fasting plasma glucose, triglycerides, total and LDL cholesterol, and, in some studies, systolic and diastolic blood pressure, while effects on body weight and BMI were small and inconsistent across trials. These cardiometabolic gains are clinically relevant, yet they again position berberine as a complementary therapy targeting risk factors rather than as a primary weight‑loss agent. In the psychiatric setting, a 12‑week randomized, double‑blind trial in 113 patients with schizophrenia spectrum disorders and antipsychotic‑induced metabolic syndrome showed that adjunctive berberine 600 mg/day attenuated further weight gain and produced statistically greater reductions in weight (≈1.1 kg), BMI, waist circumference, total and LDL cholesterol, and HbA1c compared with placebo, without worsening psychotic symptoms. While these absolute weight changes are modest, they are clinically meaningful in a population at high risk for rapid, medication‑related weight accrual and highlight berberine’s potential as a protective adjunct rather than as a curative obesity drug. Overall, the human trial data depict berberine as a multi‑target metabolic modulator that delivers small reductions in weight and central adiposity, with more consistent benefits for hepatic fat, glycaemic control, and atherogenic lipids, an effect profile that contrasts sharply with the dramatic “natural Ozempic” narrative common in lay media [15,21,22].

Beyond The Scale: Glucose, Lipids, and Cardiometabolic Risk

Beyond effects on body mass, berberine shows a more consistent and clinically relevant signal on glycaemic control, lipid metabolism, and systemic inflammation. In patients with type 2 diabetes, randomized trials and pooled analyses demonstrate significant reductions in fasting plasma glucose and HbA1c when berberine is used either as monotherapy or as an adjunct to standard oral hypoglycemics. In an early but influential trial, berberine 1.5 g/day lowered HbA1c from 9.5% to 7.5% over three months, with parallel declines in fasting glucose, postprandial glucose, fasting insulin, and HOMA‑IR; in a combination arm, add‑on berberine reduced HbA1c from 8.1% to 7.3% without major weight change, and its glycaemic effect was described as comparable to metformin. Subsequent meta‑analyses of randomized controlled trials in type 2 diabetes and prediabetes confirm that berberine, alone or combined with standard agents, significantly improves fasting and postprandial glucose and reduces HbA1c by roughly 0.5–0.8 percentage points on average, with larger effects in individuals with higher baseline glycaemic indices and in those receiving 1.5–2 g/day. Mechanistically, these clinical benefits align with experimental data showing that berberine enhances glucose uptake in peripheral tissues, suppresses hepatic gluconeogenesis, and improves insulin signalling through AMPK activation and downstream modulation of key metabolic enzymes and transporters. As a result, even in trials where body weight changes are small, berberine often produces meaningful improvements in glycaemic indices and insulin resistance, underscoring its role as a metabolic modulator rather than a pure weight‑loss agent [1,2,23,24,25,26].

Berberine’s impact on lipid profiles and inflammatory markers further extends its potential cardiometabolic benefits beyond the number on the scale. Multiple randomized trials and meta‑analyses in dyslipidaemic or high‑risk populations show that berberine supplementation significantly reduces total cholesterol, LDL‑cholesterol, and triglycerides, with some studies also reporting modest increases in HDL‑cholesterol. A meta‑analysis of 11 randomized trials involving 874 participants found mean reductions of approximately 0.6 mmol/L in total cholesterol, 0.5 mmol/L in triglycerides, and 0.6 mmol/L in LDL‑cholesterol, accompanied by a small but significant rise in HDL‑cholesterol effects that were observed even when body‑weight changes were minimal. An umbrella review of meta‑analyses similarly concluded that berberine improves LDL, total cholesterol, and triglycerides and can be considered a complementary treatment option for hyperlipidaemia, albeit with heterogeneity in study quality and dosing. Parallel evidence from systematic reviews of inflammatory markers indicates that berberine supplementation lowers circulating C‑reactive protein (CRP), with pooled data from randomized trials showing a mean reduction of around 0.6 mg/L, and broader analyses in metabolic syndrome populations suggesting significant decreases in CRP and other inflammatory mediators. These anti‑inflammatory and lipid‑modifying actions, occurring sometimes independently of large shifts in body weight, support the view that berberine may contribute to cardiovascular risk reduction through improvements in atherogenic dyslipidaemia and chronic low‑grade inflammation, even when its direct effects on adiposity are modest [17,27,28,29,30,31].

Limitations, Safety, and Practical Considerations

Across clinical trials, berberine has typically been administered in oral doses ranging from 500 to 1,500 mg per day, most often divided into two or three doses with meals and continued for approximately 8 to 24 weeks. Meta‑analyses in metabolic syndrome and dyslipidaemia indicate that intervention durations between 84 and 140 days are common, with some subgroup analyses suggesting that short‑term courses (≤90 days) may exert more pronounced effects on lipid parameters such as LDL‑cholesterol than longer regimens. Importantly, there is substantial variability in the formulations studied: some trials use purified berberine hydrochloride, whereas others evaluate berberine salts or fixed‑dose combinations, including berberine–ursodeoxycholate (BUDCA) in phase 2 studies for type 2 diabetes and NASH. Several of the more impressive effects on hepatic steatosis and glycaemic control derive from these proprietary combination products rather than from generic berberine alone, which complicates direct extrapolation to over‑the‑counter supplements and underscores the need to interpret “berberine” results in light of the specific formulation tested [13,14,19,20,21].

From a safety perspective, berberine is generally well tolerated, but gastrointestinal adverse effects are frequent and represent the main limitation in routine practice. Across randomized trials and pooled analyses, participants receiving berberine report higher rates of diarrhea, abdominal discomfort, nausea, flatulence, and constipation compared with placebo, although most events are mild to moderate in severity. In one study of patients with type 2 diabetes given 500 mg three times daily for 13 weeks, approximately one‑third experienced gastrointestinal symptoms, including diarrhea, abdominal pain, or constipation, which occasionally necessitated dose reduction or temporary discontinuation. Mechanistic work suggests that alterations in gut microbiota composition and bile acid metabolism may contribute to diarrhea in susceptible individuals, but these observations remain exploratory. Beyond local gut effects, there is growing concern about potential drug–drug interactions: in vitro and translational data indicate that berberine can inhibit cytochrome P450 enzymes (notably CYP3A4) and drug transporters such as P‑glycoprotein, raising the theoretical risk of increased exposure to co‑administered agents including statins, some antihypertensives, certain oral hypoglycaemics, and anticoagulants. Robust, pregnancy‑specific or lactation‑specific safety data are lacking, and most experts advise against use in pregnancy, breastfeeding, and in patients with advanced hepatic or renal impairment, where altered drug handling and polypharmacy are common; a cautious, individualized risk–benefit assessment is therefore essential [21,23,32,33,34].

Despite an expanding evidence base, important methodological limitations constrain the strength and generalizability of conclusions about berberine’s metabolic effects. Many randomized controlled trials enrol relatively small samples (often fewer than 100 participants per arm), limiting power to detect rare adverse events and modest differences in hard clinical outcomes. Diagnostic criteria and inclusion thresholds for metabolic syndrome, insulin resistance, or dyslipidaemia vary substantially between studies, and background lifestyle interventions such as dietary counselling, physical activity recommendations, or concomitant pharmacotherapy are inconsistently standardized or reported. Follow‑up rarely extends beyond the active treatment period, so data on weight or metabolic relapse after discontinuation are sparse, and virtually no trials are powered for cardiovascular events or long‑term microvascular outcomes. Furthermore, the majority of participants across trials have established metabolic dysregulation such as type 2 diabetes, metabolic syndrome, dyslipidaemia, or NAFLD, often with multiple concomitant medications. As a result, extrapolating observed benefits to lean, metabolically healthy individuals seeking berberine primarily for cosmetic fat loss is not evidence‑based, and clinicians should resist conflating improvements in high‑risk clinical populations with efficacy in low‑risk consumers exposed to social‑media marketing [13,14,15,21,34,35].

Berberine vs the Hype: Reframing Expectations

Across popular media, berberine is frequently promoted as a “natural GLP‑1,” “nature’s Ozempic,” or stand‑alone “fat burner,” with influencer testimonials suggesting rapid, clinically meaningful weight loss in otherwise healthy users. This narrative stands in stark contrast to the clinical trial literature, where randomized studies and meta‑analyses consistently show only modest reductions in body weight, typically around 1-2 kg, typically around 1–2 kg, with similarly small changes in BMI and waist circumference and considerable heterogeneity across populations and study designs. Much of the enthusiasm in lay channels rests on mechanistic observations like AMPK activation, enhanced fatty acid oxidation, improved insulin signalling and glucose uptake that are biologically compelling but do not automatically translate into large, rapid fat loss in free‑living humans. Clinical data instead indicate that berberine’s strongest and most reproducible signals are in surrogate metabolic markers (fasting glucose, HbA1c, triglycerides, LDL‑cholesterol, liver fat, inflammatory indices) rather than dramatic reductions in total body weight, which is why expert commentaries caution against equating it with GLP‑1 receptor agonists in efficacy or mechanism. Framing berberine as a “natural Ozempic” therefore risks overselling benefits, under‑communicating uncertainties and side‑effects, and fostering unrealistic expectations among both clinicians and patients [1,2,4,13,14,15,16,18,20,36].

Within an evidence‑informed care model, berberine is better conceptualized as a targeted adjunct rather than as a primary anti‑obesity pharmacotherapy. The most compelling indications emerge in individuals with established metabolic disturbances such as insulin resistance or type 2 diabetes, atherogenic dyslipidaemia, NAFLD/NASH, or antipsychotic‑associated metabolic derangements, here trials and meta‑analyses demonstrate improvements in glycaemic indices, lipid parameters, liver fat, and markers of systemic inflammation, often out of proportion to the degree of weight change. In this context, berberine can be layered onto foundational lifestyle interventions, structured nutrition and physical activity programs, sleep and stress optimization and, when appropriate, guideline‑directed pharmacotherapies such as metformin, statins, GLP‑1 receptor agonists, or SGLT2 inhibitors, with the goal of incremental risk‑factor modification rather than transformative weight loss. Any decision to incorporate berberine should be individualized, taking into account baseline metabolic status, concomitant medications (and potential cytochrome P450/P‑glycoprotein interactions), comorbidities such as hepatic or renal dysfunction, tolerability of gastrointestinal side‑effects, patient preferences, and cost. For metabolically healthy individuals seeking cosmetic fat reduction, the current evidence does not support routine berberine use as a weight‑loss strategy, and clinicians should explicitly communicate that its role is as a complementary tool within comprehensive cardiometabolic risk management, not as a substitute for established therapies or a shortcut to rapid fat loss [13,14,15,18,20,21,22,23,32,33,34,35,36].

Practical Takeaways for Patients and Clinicians

Evidence syntheses suggest that berberine is most likely to confer clinically relevant benefit in patients with demonstrable metabolic dysregulation rather than in metabolically healthy individuals. Systematic reviews of randomized trials indicate meaningful improvements in fasting glucose, HbA1c, triglycerides, LDL‑cholesterol, and markers of insulin resistance among people with type 2 diabetes or prediabetes, particularly when baseline glycaemic control is suboptimal. Similar meta‑analytic signals are seen in adults with metabolic syndrome and dyslipidaemia, where berberine supplementation improves several syndrome components, including waist circumference, triglycerides, fasting glucose, and blood pressure with a favourable short‑term safety profile. Patients with NAFLD/NASH and coexisting type 2 diabetes appear to benefit from combination formulations such as berberine–ursodeoxycholate, which in phase 2 trials reduced MRI‑quantified liver fat, improved liver enzymes and glycaemic indices, and produced modest weight loss. A further niche is antipsychotic‑associated metabolic disturbance, where adjunctive berberine attenuates weight gain and improves lipids and glycaemic markers in individuals receiving second‑generation antipsychotics. In contrast, there is little high‑quality evidence in metabolically healthy, normal‑weight or mildly overweight individuals seeking primarily aesthetic fat loss; given the small average effect sizes on body weight in high‑risk cohorts, the incremental benefit in such populations is likely to be minimal and may not justify cost, pill burden, or potential drug–drug interactions [13,14,15,18,20,21,22,37,38,39].

For both clinicians and patients, the responsible use of berberine begins with embedding it within established pillars of cardiometabolic care rather than treating it as a standalone solution. Lifestyle interventions like energy‑appropriate, nutrient‑dense dietary patterns; regular resistance and aerobic exercise; adequate sleep; and stress‑management strategies, remain the foundation for weight and risk‑factor modification, with pharmacologic therapies such as metformin, GLP‑1 receptor agonists, SGLT2 inhibitors, and statins deployed according to guideline‑based indications. Within this framework, berberine can be considered as an adjunct for selected patients with type 2 diabetes, metabolic syndrome, NAFLD/NASH, or antipsychotic‑related metabolic issues, ideally after a careful medication review to assess cytochrome P450 and P‑glycoprotein interaction risk and to avoid duplication or conflict with existing therapies. Pragmatically, it is reasonable to define a finite trial period, commonly 8–12 weeks at evidence‑based doses during which fasting glucose, HbA1c (if applicable), fasting lipids, liver enzymes, and relevant symptoms (e.g., gastrointestinal tolerance) are monitored, with cessation if pre‑specified metabolic or symptomatic targets are not met or if adverse effects occur. Shared decision‑making is crucial: patients should be informed that expected weight changes are modest, that benefits primarily involve metabolic markers rather than dramatic fat loss, and that any use should be periodically re‑evaluated rather than continued indefinitely by default [13,14,15,21,32,33,34,39,40].

Mechanistic Gold, Clinical Bronze

Taken together, the available data position berberine as a compound with impressive mechanistic credentials but more modest clinical performance in the specific domain of fat loss. At the cellular and organ level, berberine activates AMPK, enhances glucose uptake, suppresses hepatic gluconeogenesis, improves lipid handling, and exerts anti‑inflammatory effects, an integrated profile that maps neatly onto the pathophysiology of insulin resistance, dyslipidaemia, and fatty liver disease. These findings, reinforced by consistent improvements in glycaemic indices, triglycerides, LDL‑cholesterol, and markers of hepatic steatosis in human studies, justify describing berberine as a metabolically active nutraceutical. However, when the focus is narrowed to changes in body weight, BMI, or waist circumference, the signal is clearly one of “clinical bronze”: pooled effects in randomized trials are small, heterogeneous, and far removed from the dramatic weight‑loss typically associated with GLP‑1 receptor agonists or other dedicated anti‑obesity pharmacotherapies.

In this context, the most defensible way to integrate berberine into practice is to frame it as a supportive adjunct within a broader, evidence‑based cardiometabolic strategy rather than as a magic bullet for weight loss. For selected patients with type 2 diabetes or prediabetes, metabolic syndrome with atherogenic dyslipidaemia, NAFLD/NASH, or antipsychotic‑associated metabolic complications, a time‑limited trial of berberine, embedded within structured lifestyle interventions and guideline‑directed pharmacotherapy may offer incremental gains in metabolic control. Its use should be individualized, taking into account baseline risk, concomitant medications, comorbidities, tolerability, and patient preferences, with clear treatment goals and regular reassessment to determine whether continued therapy is warranted. For metabolically healthy individuals primarily seeking aesthetic fat reduction, the discrepancy between online hype and actual effect sizes needs to be communicated explicitly: berberine is not a substitute for foundational lifestyle change, nor a stand‑alone solution for obesity, but rather one optional tool among many in the long‑term management of cardiometabolic risk.

Reference

  1. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States. Diabetes [Internet]. 2006 Aug 1;55(8):2256–64. Available from: https://diabetes.diabetesjournals.org/content/55/8/2256
  2. Ren G, Guo JH, Qian YZ, Kong WJ, Jiang JD. Berberine Improves Glucose and Lipid Metabolism in HepG2 Cells Through AMPKα1 Activation. Frontiers in Pharmacology. 2020 May 8;11.
  3. Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang Y, et al. Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis. Xu A, editor. PLoS ONE. 2011 Feb 3;6(2):e16556.
  4. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. American Journal of Physiology Endocrinology and Metabolism [Internet]. 2009 Apr 1;296(4):E812-819. Available from: https://pubmed.ncbi.nlm.nih.gov/19176354/
  5. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States. Diabetes [Internet]. 2006 Aug 1;55(8):2256–64. Available from: https://diabetes.diabetesjournals.org/content/55/8/2256
  6. Choi YJ, Lee KY, Jung SH, Kim HS, Shim G, Kim MG, et al. Activation of AMPK by berberine induces hepatic lipid accumulation by upregulation of fatty acid translocase CD36 in mice. Toxicology and Applied Pharmacology. 2017 Feb;316:74–82.
  7. Dai J, Huang X, Zhang C, Gao J. Mechanisms of lipid metabolism promoted by berberine via peroxisome proliferator‐activated receptor gamma during in vitro maturation of porcine oocytes. Animal Science Journal. 2021 Jan;92(1).
  8. Wu L, Xia M, Duan Y, Zhang L, Jiang H, Hu X, et al. Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans. Cell Death & Disease [Internet]. 2019 Jun 13;10(6):1–18. Available from: https://www.nature.com/articles/s41419-019-1706-y#Sec10
  9. Zhang Z, Zhang H, Li B, Meng X, Wang J, Zhang Y, et al. Berberine activates thermogenesis in white and brown adipose tissue. Nature Communications. 2014 Nov 25;5(1).
  10. Xu Y, Yu T, Ma G, Zheng L, Jiang X, Yang F, et al. Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway. International Journal of Biological Sciences [Internet]. 2021 Jan 1 [cited 2023 Oct 28];17(12):3173–87. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375237/
  11. Wang C, Yang Y, Chen J, Dai X, Xing C, Zhang C, et al. Berberine Protects against High-Energy and Low-Protein Diet-Induced Hepatic Steatosis: Modulation of Gut Microbiota and Bile Acid Metabolism in Laying Hens. International Journal of Molecular Sciences. 2023 Dec 9;24(24):17304–4.
  12. Teresa, Juan-Carlos Gálvez-Ruíz, Alejandra A, Mario-Alberto Leyva-Peralta. Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent. Pharmaceuticals. 2025 Jan 31;18(2):193–3.
  13. Zamani M, Mahnaz Zarei, Mahlagha Nikbaf-Shandiz, Hosseini S, Farideh Shiraseb, Omid Asbaghi. The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis. Frontiers in Nutrition [Internet]. 2022 Oct 14;9. Available from: https://ncbi.nlm.nih.gov/pmc/articles/PMC9614282/
  14. Asbaghi O, Ghanbari N, shekari M, Reiner Ž, Amirani E, Hallajzadeh J, et al. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition ESPEN. 2020 Aug;38:43–9.
  15. Shi L, Wang W, Jing C, Hu J, Liao X. Berberine and health outcomes: an overview of systematic reviews. BMC Complementary Medicine and Therapies. 2025 Apr 23;25(1).
  16. Elahi Vahed I, Shahir-Roudi E, Nojumi S, Golmohammadi S, Moradi Shahrebabak M, Sharafi Tafreshi Moghadam N, et al. The effect of berberine on obesity indices: a systematic review and meta-analysis. International journal of obesity (2005) [Internet]. 2026 Jan;50(1):53–73. Available from: https://pubmed.ncbi.nlm.nih.gov/41310257/
  17. Zeynab Kavyani, Erfan shahhosseini, Amir Hossein Moridpour, Falahatzadeh M, Mahdi Vajdi, Vali Musazadeh, et al. The effect of berberine supplementation on lipid profile and obesity indices: An umbrella review of meta-analysis. PharmaNutrition. 2023 Dec 1;26:100364–4.
  18. Lei L, Wang B, Zhao L, Li J, Yan X, Jiang J, et al. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD. JAMA Network Open [Internet]. 2026 Jan 16;9(1):e2554152–2. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2844037
  19. Harrison S, Gunn N, Neff G, Kohli A, Macconell L, Loomba R. Effects of HTD1801 (Berberine Ursodeoxycholate) on Non-Invasive Fibrosis Markers in Subjects with Presumed NASH and Type 2 Diabetes [Internet]. [cited 2026 Mar 16]. Available from: https://hightidetx.com/wp-content/uploads/2024/11/Harrison_AASLD-2021_012-NASH-Non-invasive_Poster-Final.pdf
  20. Harrison SA, Gunn N, Neff GW, Kohli A, Liu L, Flyer A, et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nature Communications. 2021 Sep 17;12(1).
  21. Liu D, Zhao H, Zhang Y, Hu J, Xu H. Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Frontiers in Pharmacology. 2025 Jul 16;16.
  22. Chan M, Qin Z, Man S, Lam M, Lai WH, Ng RMK, et al. Adjunctive berberine reduces antipsychotic‐associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial. Psychiatry and Clinical Neurosciences. 2022 Jan 18;76(3):77–85.
  23. Yin J, Xing H, Ye J. Efficacy of Berberine in Patients with Type 2 Diabetes Mellitus. Metabolism. 2008 May;57(5):712–7.
  24. Xie W, Su F, Wang G, Peng Z, Xu Y, Zhang Y, et al. Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. Frontiers in Pharmacology [Internet]. 2022;13:1015045. Available from: https://pubmed.ncbi.nlm.nih.gov/36467075/
  25. Liang Y, Xu X, Yin M, Zhang Y, Huang L, Chen R, et al. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. Endocrine Journal. 2019;66(1):51–63.
  26. Guo J, Chen H, Zhang X, Lou W, Zhang P, Qiu Y, et al. The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oxidative Medicine and Cellular Longevity [Internet]. 2021;2021:2074610. Available from: https://pubmed.ncbi.nlm.nih.gov/34956436/
  27. Cavalheiro DM, Silva K de A, Cardoso BEP, Dias TM da S, Moura AR da S, Melo SR de S, et al. Efeito da suplementação com berberina nas dislipidemias em humanos: Uma revisão sistemática. Research, Society and Development [Internet]. 2021 Apr 29 [cited 2026 Mar 16];10(5):e9710514741. Available from: https://rsdjournal.org/rsd/article/view/14741
  28. Beba M, Djafarian K, Shab-Bidar S. Effect of Berberine on C-reactive protein: A systematic review and meta-analysis of randomized controlled trials. Complementary Therapies in Medicine. 2019 Oct;46:81–6.
  29. Ju J, Li J, Lin Q, Xu H. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine. 2018 Nov;50:25–34.
  30. Dong H, Zhao Y, Zhao L, Lu F. The Effects of Berberine on Blood Lipids: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. Planta Medica. 2013 Mar 19;79(06):437–46.
  31. Lu Y, Zhang X, He J, Dai Z, Shi P, Lu Y, et al. The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials. Inflammopharmacology. 2022 Mar 29;30(3):1063–77.
  32. Cheng H, Liu J, Tan Y, Feng W, Peng C. Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine. Journal of Pharmaceutical Analysis. 2021 Oct;
  33. Asghari P, Babaei A, Zamanian N, Eshtivani EN -. Berberine’s impact on health: Comprehensive biological, pharmacological, and nutritional perspectives. Metabolism Open [Internet]. 2025 Dec;28:100399. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12516553/
  34. Clinic C. Berberine: What It Is, Benefits and Side Effects [Internet]. Cleveland Clinic. 2025. Available from: https://health.clevelandclinic.org/berberine
  35. Ilyas Z, Perna S, Al-thawadi S, Alalwan TA, Riva A, Petrangolini G, et al. The effect of Berberine on weight loss in order to prevent obesity: A systematic review. Biomedicine & Pharmacotherapy. 2020 Jul;127:110137.
  36. Paolo Bellavite, Fazio S, Affuso F. A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention. Molecules. 2023 Jun 1;28(11):4491–1.
  37. Ren S, Ma X, Wang R, Liu H, Wei Y, Wei S, et al. Preclinical Evidence of Berberine on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Animal Studies. Frontiers in Pharmacology [Internet]. 2021 Sep 9 [cited 2023 Feb 8];12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458904/
  38. Ji L, Ma J, Ma Y, Cheng Z, Gan S, Yuan G, et al. Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes. JAMA Network Open. 2025 Mar 3;8(3):e2462185–5.
  39. Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y, et al. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in Pharmacology. 2021 Apr 26;12.
  40. Feng X, Sureda A, Jafari S, Memariani Z, Tewari D, Annunziata G, et al. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics. 2019;9(7):1923–51.

‌

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading